---
title: "Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Product information and disease description"
description: "Formulary evidence on Zeleciment rostudirsen (z-rostudirsen, DYNE-251) in Duchenne muscular dystrophy: Product information and disease description. Covers Product description and Place of product in therapy. 62 evidence topics quoted from 50 sources."
canonical: "https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/product-information-and-disease-description"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Fast Track designation

> “the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DYNE-251”

Source: [Dyne Therapeutics (2022)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-receives-fda-fast-track-designation-dyne-251/)

<a id="topic-2.1.1-2"></a>

##### Orphan drug and rare pediatric disease designations

> “was granted U.S. Food and Drug Administration (FDA) orphan drug and rare pediatric disease designations.”

Source: [Dyne Therapeutics (2023)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-receives-fda-orphan-drug-and-rare-pediatric/)

<a id="topic-2.1.1-3"></a>

##### Breakthrough Therapy designation

> “has granted Breakthrough Therapy Designation to DYNE-251”

Source: [Dyne Therapeutics breakthrough therapy designation announcement (2025)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-fda-breakthrough-therapy-0)

<a id="topic-2.1.1-4"></a>

##### Regulatory status: Under review; BLA submitted May 2026, FDA action date January 2027

> “WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE)”
> “announced the submission of a Biologics License Application (BLA)”

Source: [Dyne Therapeutics Biologics License Application submission announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-submission-biologics-license)

> “WALTHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE)”
> “Dyne’s BLA is under priority review by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of January 21, 2027.”

Source: [Dyne Therapeutics third quarter 2026 results announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-third-quarter-2026-financial-results)

<a id="topic-2.1.1-5"></a>

##### Priority Review and FDA action date

> “Priority Review granted; PDUFA target action date set for January 21, 2027”

Source: [Dyne Therapeutics Biologics License Application acceptance announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-us-fda-acceptance-biologics-license)

<a id="topic-2.1.1-6"></a>

##### Launch: Anticipated in the first quarter of 2027

> “WALTHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE)”
> “Dyne continues to expect a potential U.S. launch of z-rostudirsen in Q1 2027, assuming approval is received on the anticipated timeline.”

Source: [Dyne Therapeutics third quarter 2026 results announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-third-quarter-2026-financial-results)

<a id="topic-2.1.1-7"></a>

##### FDA Advisory Committee meeting date

No evidence found.

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Dyne Therapeutics

> “Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for zeleciment rostudirsen”

Source: [Dyne Therapeutics Biologics License Application submission announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-submission-biologics-license)

<a id="topic-2.1.2.1-2"></a>

###### Product names

> “zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251)”

Source: [Dyne Therapeutics clinical trials page](https://www.dyne-tx.com/clinical-trials/)

<a id="topic-2.1.2.1-3"></a>

###### Drug class and molecular construction

> “a phosphorodiamidate morpholino oligomer (PMO) conjugated to an antigen-binding fragment (Fab) that binds to the transferrin receptor 1 (TfR1).”

Source: [Dyne Therapeutics pipeline page](https://www.dyne-tx.com/pipeline/)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Investigational formulation and recorded strengths

| Registry field | Quoted record |
| --- | --- |
| Pharmaceutical form | “Solution for infusion” |
| First recorded strength, mg | “200” |
| Second recorded strength, mg | “350” |

Source: [EU Clinical Trials Register 2021-005478-24](https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005478-24/BE)

<a id="topic-2.1.2.2-2"></a>

###### Commercial formulation, packaging, and storage requirements

No evidence found.

<a id="topic-2.1.2.2-3"></a>

###### Material safety data sheet

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### Therapeutic approach

> “Exon Skipping”

Source: [DMD Hub](https://dmdhub.org/trials/dyne-therapeutics-dyne-251/)

<a id="topic-2.1.2.4-2"></a>

###### AHFS classification code

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Population proposed for treatment

> “treatment of individuals with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping”

Source: [Dyne Therapeutics Biologics License Application submission announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-submission-biologics-license)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Exon-skipping mechanism

> “restore the open reading frame of the DMD transcript and enable the translation of a shortened but functional dystrophin protein”

Source: [Desjardins et al. (2022a)](https://www.dyne-tx.com/wp-content/uploads/gkac641.pdf)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Preclinical FORCE–M23D evidence

> “Importantly, FORCE–M23D treatment resulted in improved functional outcomes compared with administration of unconjugated M23D.”

Source: [Desjardins et al. (2022a)](https://www.dyne-tx.com/wp-content/uploads/gkac641.pdf)

<a id="topic-2.1.2.6.2-2"></a>

###### FORCE platform toxicology: repeat-dose studies in cynomolgus monkeys

> “Reticulocytes were transiently decreased 24-72 hrs after administration of either FORCE-PMO or FORCE-ASO but not FORCE-siRNA”

Source: [Davis et al. (2026)](https://www.dyne-tx.com/wp-content/uploads/Davis_SOT_March_2026.pdf)

<a id="topic-2.1.2.6.2-3"></a>

###### FORCE-M23D and CNS outcomes: hTfR1/mdx mice

> “A single dose of FORCE-M23D leads to durable resolution of anxiety in hTfR1/mdx mice”

Source: [Desjardins et al. (2025)](https://www.dyne-tx.com/wp-content/uploads/Desjardins_2025_WMS_DMD%20CNS%20Poster.pdf)

<a id="topic-2.1.2.6.2-4"></a>

###### FORCE-M23D muscle pathology: D2-mdx mouse model

> “FORCE-M23D achieved robust dystrophin restoration to the sarcolemma of skeletal muscles and improved muscle morphology of D2-mdx mice.”

Source: [Desjardins et al. (2023)](https://www.dyne-tx.com/wp-content/uploads/Desjardins_Et_al_MDA%202023_D2_Mdx_Mouse.pdf)

<a id="topic-2.1.2.6.2-5"></a>

###### DYNE-251 preclinical exon skipping: nonhuman primates

> “DYNE-251 led to pronounced exon 51 skipping in the heart, diaphragm and quadriceps 8 weeks after the first dose”

Source: [Desjardins et al. (2022b)](https://www.dyne-tx.com/wp-content/uploads/2022_WMS_Poster_FINAL.pdf)

<a id="topic-2.1.2.6.2-6"></a>

###### DELIVER: dose-dependent target engagement

> “DYNE-251 Demonstrated Dose-Dependent Exon Skipping and Delivery of PMO to Muscle”

Source: [De Waele et al. (2024)](https://www.dyne-tx.com/wp-content/uploads/De_Waele_DELIVER_WMS_2024.pdf)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Muscle drug concentration, initial DELIVER data

> “DYNE-251 showed a mean 657 ng/g PMO muscle drug concentration at 6 months.”

Source: [Dyne Therapeutics initial DELIVER clinical data announcement (2024)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-positive-initial-clinical-data)

<a id="topic-2.1.2.6.3-2"></a>

###### Plasma exposure, clearance, half-life, and accumulation

No evidence found.

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### DELIVER: non-ambulatory participant eligibility

> “A non-ambulatory participant must have been non-ambulatory for <2 years before enrollment.”

Source: [University of California San Diego (2026)](https://clinicaltrials.ucsd.edu/trial/NCT05524883)

<a id="topic-2.1.2.8-2"></a>

###### Renal impairment, hepatic impairment, pregnancy, and lactation

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Zeleciment rostudirsen

<a id="topic-2.1.2.9.1-1"></a>

###### Drug–drug, drug–food, and drug–disease interactions

No evidence found.

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Zeleciment rostudirsen on Other Drugs

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Proposed dose, route, and frequency

> “Proposed dosing regimen of 20 mg/kg administered intravenously once every 4 weeks (Q4W)”

Source: [Dyne Therapeutics Biologics License Application submission announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-submission-biologics-license)

<a id="topic-2.1.2.10.1-2"></a>

###### Dose convention

> “Doses provided refer to PMO component of DYNE 251.”

Source: [Naylor et al. (2023)](https://www.dyne-tx.com/wp-content/uploads/Naylor_Et_al_MDA_2023_DELIVER_TiP.pdf)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Investigational route of administration

> “Intravenous use”

Source: [EU Clinical Trials Register 2021-005478-24](https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005478-24/BE)

<a id="topic-2.1.2.10.2-2"></a>

###### Final administration-site requirements

No evidence found.

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Commercial distribution strategy

No evidence found.

<a id="topic-2.1.2.11-2"></a>

###### Commercial patient support program

No evidence found.

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### DELIVER: concomitant glucocorticoid requirement

> “a stable dosage of glucocorticoids for ≥12 weeks”

Source: [Naylor et al. (2023)](https://www.dyne-tx.com/wp-content/uploads/Naylor_Et_al_MDA_2023_DELIVER_TiP.pdf)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Zeleciment rostudirsen on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### Z-rostudirsen-specific effect on quality measures

No evidence found.

<a id="topic-2.1.2.13-2"></a>

###### Evaluation of care-consideration implementation

> “We identify key elements of care and present suggestions for their use in evaluation and research.”

Source: [Ong et al. (2018)](https://stacks.cdc.gov/view/cdc/61439)

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Treatment alternatives: eteplirsen prescribing information

| Product-information element | Direct quotation |
| --- | --- |
| Mutation requirement | “amenable to exon 51 skipping” |
| Dose | “30 milligrams per kilogram of body weight once weekly” |
| Administration | “intravenous infusion over 35 to 60 minutes” |

Source: [FDA EXONDYS 51 prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/206488s035lbl.pdf)

<a id="topic-2.1.2.14-2"></a>

###### Head-to-head comparison with an approved therapy

No evidence found.

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Inheritance

> “Dystrophinopathies are inherited in an X-linked manner.”

Source: [Duvuru et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1119/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Duchenne muscular dystrophy

<a id="topic-2.2.1.2.1-1"></a>

###### Global birth prevalence

> “the pooled global DMD birth prevalence was 19.8 (95% CI:16.6-23.6) per 100,000 live male births.”

Source: [Crisafulli et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7275323/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Duchenne muscular dystrophy

<a id="topic-2.2.1.2.2-1"></a>

###### U.S. population estimates

> “~12,000 US DMD population”
> “~1,600 US Exon 51 skip amenable DMD”

Source: [Dyne Therapeutics investor presentation (2026)](https://investors.dyne-tx.com/static-files/9a27ae49-fa3f-4bd6-8711-029549461129)

<a id="topic-2.2.1.2.2-2"></a>

###### Global male prevalence

> “The pooled global DMD prevalence was 7.1 cases (95% CI: 5.0-10.1) per 100,000 males”

Source: [Crisafulli et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7275323/)

<a id="topic-2.2.1.2.2-3"></a>

###### Updated exon-skipping applicability

> “Exon 51 was the most relevant target and was applicable for 10.6% of all mutations and 17.2% of large deletions.”

Source: [Leckie et al. (2024)](https://doi.org/10.3390/genes15111489)

Additional sources: [Aartsma-Rus et al. (2009)](https://onlinelibrary.wiley.com/doi/10.1002/humu.20918)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Genotype and loss of ambulation in corticosteroid-treated patients

> “earlier age at LoA for the exon 51 skip amenable cohort (p < .001) when compared with the rest of the cohort.”

Source: [Zygmunt et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1002/mus.28255)

<a id="topic-2.2.1.3-2"></a>

###### Survival in more recent birth cohorts

> “patients born after 1990 have a median life expectancy of 28.1 years (95% CI 25.1, 30.3).”

Source: [Broomfield et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8665435/)

Additional sources: [Muntoni et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36725339/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Pathophysiology

> “Without a working DMD gene, the body can’t make enough working dystrophin protein.”
> “Without dystrophin, muscles can’t repair themselves properly.”
> “This eventually causes muscle weakness.”

Source: [Health Resources and Services Administration](https://newbornscreening.hrsa.gov/conditions/duchenne-muscular-dystrophy)

Additional sources: [de Feraudy et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33159473/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Genetic patient selection

> “confirmed DMD mutation in the dystrophin gene characterized by exon deletion amenable to exon 51 skipping.”

Source: [DMD Hub](https://dmdhub.org/trials/dyne-therapeutics-dyne-251/)

<a id="topic-2.2.1.5-2"></a>

###### Diagnostic delay in males without a family history of muscular dystrophy

> “Time between noticing signs and diagnosis was about 2.5 years”
> “Average age at diagnosis was 5 years”

Source: [Centers for Disease Control and Prevention (2025)](https://www.cdc.gov/muscular-dystrophy/research/summary.html)

Additional sources: [Fratter et al. (2020)](https://www.nature.com/articles/s41431-020-0643-7)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Motor symptoms: early weakness and developmental delay

> “DMD is characterized by early onset and progressive weakness, motor delays”

Source: [Duvuru et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1119/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Clinical presentation and complications

> “progressive respiratory issues, decline in cardiac function, constipation, osteopenia, and Increased mortality.”

Source: [Duvuru et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1119/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Duchenne muscular dystrophy

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Caregiver burden

> “Anxiety and depression, recorded in up to 70 % of caregivers depending on patients' health and mental status”

Source: [Landfeldt et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4859858/)

<a id="topic-2.2.1.8.1-2"></a>

###### Family-caregiver health-state utilities

> “Mean utility scores were highest for HS1 (early ambulatory: 0.717) and lowest for HS8 (no hand-to-mouth function, full-time ventilation: 0.477).”

Source: [Borecka et al. (2026)](https://link.springer.com/article/10.1186/s41687-026-01055-8)

<a id="topic-2.2.1.8.1-3"></a>

###### Disease-specific utility measurement

> “DMD-QoL utilities did not vary meaningfully across health states compared with HUI-2 scores, which tended to decline with deteriorating mobility.”

Source: [Bever et al. (2026)](https://link.springer.com/article/10.1007/s12325-026-03700-6)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### DMD economic-burden systematic review

> “the mean per-patient annual direct medical cost of illness (in 2025 international US dollars) was estimated at between $2620 and $209,980”

Source: [Landfeldt et al. (2026)](https://link.springer.com/article/10.1007/s40273-026-01610-7)

<a id="topic-2.2.1.8.2-2"></a>

###### U.S. healthcare costs

> “The DMD and non-MD cohorts included 782 matched pairs.”

Source: [Scavina et al. (2026)](https://link.springer.com/article/10.1007/s41669-025-00612-z)

<a id="topic-2.2.1.8.2-3"></a>

###### U.S. healthcare costs: mean total healthcare costs, DMD versus non-MD

> “(US$103,826.05 ± 309,335.71 versus US$3225.30 ± 13,865.14; p < 0.0001) per patient per year”

Source: [Scavina et al. (2026)](https://link.springer.com/article/10.1007/s41669-025-00612-z)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Duchenne muscular dystrophy on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Annual productivity-cost estimates

> “the mean per-patient annual indirect (productivity) cost between $400 and $48,390.”

Source: [Landfeldt et al. (2026)](https://link.springer.com/article/10.1007/s40273-026-01610-7)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Genetic-testing financial assistance

> “PPMD has a genetic testing program called Decode Duchenne that provides FREE genetic testing to eligible individuals.”

Source: [Parent Project Muscular Dystrophy genetic testing page](https://www.parentprojectmd.org/about-duchenne/genetic-causes/genetic-testing/)

<a id="topic-2.2.1.8.4-2"></a>

###### Product-specific economic effect of eligibility testing

No evidence found.

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Corticosteroids

<a id="topic-2.2.2.1.1-1"></a>

###### Corticosteroids

> “Steroids remain the current gold standard for Duchenne treatment.”

Source: [Parent Project Muscular Dystrophy caring for Duchenne page](https://www.parentprojectmd.org/care/for-healthcare-providers/caring-for-duchenne/)

<a id="topic-2.2.2.1.1-2"></a>

###### Daily corticosteroid regimens

> “At treatment initiation (between 4-6 years), the recommended regimen is daily (prednisolone, deflazacort or vamorolone).”

Source: [Guglieri et al. (2025a)](https://img1.wsimg.com/blobby/go/c41fb68b-e89f-48ad-ac1b-afa320649a21/downloads/5c451111-82c2-484e-91ce-747526149a4b/Final%20Corticosteroids%20Guidance.pdf?ver=1777992903816)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Exon-skipping Antisense Oligonucleotides

<a id="topic-2.2.2.1.2-1"></a>

###### Eteplirsen therapeutic class

> “antisense oligonucleotide”

Source: [FDA EXONDYS 51 prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/206488s035lbl.pdf)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Histone Deacetylase Inhibitors

<a id="topic-2.2.2.1.3-1"></a>

###### Treatment alternatives: givinostat

> “the first nonsteroidal drug approved to treat patients with all genetic variants of DMD”
> “six years of age and older”

Source: [FDA (2024)](https://www.fda.gov/news-events/press-announcements/fda-approves-nonsteroidal-treatment-duchenne-muscular-dystrophy)

<a id="topic-2.2.2.1.3-2"></a>

###### Givinostat therapeutic class

> “histone deacetylase (HDAC) inhibitor”

Source: [FDA (2024)](https://www.fda.gov/news-events/press-announcements/fda-approves-nonsteroidal-treatment-duchenne-muscular-dystrophy)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Gene Therapy

<a id="topic-2.2.2.1.4-1"></a>

###### Treatment alternatives: delandistrogene moxeparvovec-rokl

> “ambulatory patients four years of age and older”
> “Boxed Warning”
> “risk of serious liver injury and acute liver failure, including fatal outcomes”

Source: [FDA (2025)](https://www.fda.gov/news-events/press-announcements/fda-approves-new-safety-warning-and-revised-indication-limits-use-elevidys-following-reports-fatal)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Rehabilitation and Orthopaedic Care

Additional sources: [Birnkrant et al. (2018a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5869704/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Cardiac Therapies

<a id="topic-2.2.2.1.6-1"></a>

###### First-line cardiac therapies

> “angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs)”

Source: [Birnkrant et al. (2018b)](https://stacks.cdc.gov/view/cdc/53174/cdc_53174_DS1.pdf)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Respiratory Support

<a id="topic-2.2.2.1.7-1"></a>

###### Respiratory management

> “To preserve lung compliance, lung volume recruitment is indicated when FVC is 60% predicted or less”

Source: [Birnkrant et al. (2018b)](https://stacks.cdc.gov/view/cdc/53174/cdc_53174_DS1.pdf)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Bone Health and Endocrine Care

<a id="topic-2.2.2.1.8-1"></a>

###### Osteoporosis treatment

> “intravenous (and not oral) bisphosphonates as first-line therapy”

Source: [Birnkrant et al. (2018b)](https://stacks.cdc.gov/view/cdc/53174/cdc_53174_DS1.pdf)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 Psychosocial and Transition Support

Additional sources: [Birnkrant et al. (2018c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5902408/)

<a id="heading-2.2.2.1.10"></a>

###### 2.2.2.1.10 Limitations of Current Therapies

<a id="topic-2.2.2.1.10-1"></a>

###### Summary

Available treatments have different eligibility restrictions, administration requirements, and evidentiary limitations. Eteplirsen is restricted to exon 51-skipping-amenable mutations and requires weekly intravenous infusion; its labeling states that continued approval may depend on verification of clinical benefit. Delandistrogene moxeparvovec-rokl is limited to ambulatory individuals aged four years or older and carries a boxed warning for serious liver injury and acute liver failure, including fatal outcomes. The 2019 ICER assessment of eteplirsen and golodirsen is historical and is not an assessment of z-rostudirsen.

Source: [FDA EXONDYS 51 prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/206488s035lbl.pdf); [FDA (2025)](https://www.fda.gov/news-events/press-announcements/fda-approves-new-safety-warning-and-revised-indication-limits-use-elevidys-following-reports-fatal); [ICER (2019)](https://icer.org/news-insights/press-releases/dmd_evidence_report/)

<a id="topic-2.2.2.1.10-2"></a>

###### Historical assessment of eteplirsen and golodirsen

> “In the absence of persuasive evidence demonstrating clinical effectiveness, ICER is unable to calculate value-based price benchmarks for eteplirsen or golodirsen.”

Source: [ICER (2019)](https://icer.org/news-insights/press-releases/dmd_evidence_report/)

<a id="topic-2.2.2.1.10-3"></a>

###### Eteplirsen confirmatory-evidence requirement

> “Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.”

Source: [FDA EXONDYS 51 prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/206488s035lbl.pdf)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

Zeleciment rostudirsen is being developed for individuals with DMD mutations amenable to exon 51 skipping. The proposed regimen is 20 mg/kg intravenously every four weeks, with doses expressed as the PMO component. DELIVER required stable background glucocorticoids for at least 12 weeks. The reported commercial launch remains conditional on approval; final commercial distribution and administration-site requirements are not established in this report.

Source: [Dyne Therapeutics Biologics License Application submission announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-submission-biologics-license); [Naylor et al. (2023)](https://www.dyne-tx.com/wp-content/uploads/Naylor_Et_al_MDA_2023_DELIVER_TiP.pdf); [Dyne Therapeutics second quarter 2026 results announcement (2026)](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-second-quarter-2026-financial-results)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

Additional sources: [Fang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11867578/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Clinical-trial participation support

> “developed a travel service program to address the burden of clinical trial travel and enable long-distance and cross-border participation”
> “planned for home visits when feasible”

Source: [Furlong et al. (2024)](https://link.springer.com/article/10.1186/s40900-023-00535-1)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Intended therapeutic effect

> “enable the production of near-full length dystrophin in muscle and the central nervous system (CNS) to provide functional improvement.”

Source: [Dyne Therapeutics pipeline page](https://www.dyne-tx.com/pipeline/)

## Related pages
- [Zeleciment rostudirsen (z-rostudirsen): Duchenne muscular dystrophy](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Terms and abbreviations](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/terms-and-abbreviations.md)
- [Zeleciment rostudirsen (z-rostudirsen): Duchenne muscular dystrophy](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/executive-summary.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Clinical evidence](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/clinical-evidence.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Economic information and modeling report](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/economics) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/economics.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: References](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/references) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/references.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: prevalence by geography](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/prevalence) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/prevalence.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/cost-effectiveness-analyses.md)
